New drug hope for muscle weakness condition in chinese patients

NCT ID NCT07246564

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated Apr 24, 2026 · Updated 19 times

Summary

This study tests a drug called rozanolixizumab in 40 Chinese adults with generalized myasthenia gravis, a condition causing muscle weakness. The main goal is to see if the drug improves daily activities like walking and talking over 43 days. Participants must have certain antibodies and be at least 18 years old.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mg0033 20040
RECRUITING

Beijing, China
Mg0033 20172
RECRUITING

Shanghai, China
Mg0033 20180
RECRUITING

Wuhan, China
Mg0033 20184
RECRUITING

Shenzhen, China
Mg0033 20185
RECRUITING

Jinan, China
Mg0033 20204
RECRUITING

Suzhou, China
Mg0033 20269
RECRUITING

Guangzhou, China
Mg0033 20295
RECRUITING

Changsha, China
Mg0033 20347
RECRUITING

Jinan, China
Mg0033 20348
RECRUITING

Fuzhou, China
Mg0033 20349
RECRUITING

Xuzhou SHI, China

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS